MASLDNCT07646197
Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease
A study testing Peanut consumption in people with MASLD and Fatty Liver, run by Henry Ford Health System at 1 site in United States.
Trial summary
The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver. The main goal is to investigate if patients who consume peanuts have improved liver marker tests as well as metabolic profile. Read more about this study
- Who is it for?
- Ages 30 to 70 years
- Conditions the study is for
- MASLD, Fatty Liver
- What is being tested?
- Peanut consumption
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 125 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Jun 2026to 9 Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 30-70 years
- do not consume peanut/peanut butter/treenut/seeds > /week
- at least one encounter-related (stage F0/F1) MASLD diagnosis (K76.0)
- Able to understand, speak, and read English
- Mentally competent to consent
Who cannot join
- Food allergy to peanuts or peanut-containing products
- With alcohol use disorder (AUDIT screening)
- Leukemia
- Lymphoma
- Other types of cancer
- Heart or cardiovascular diseases (such as heart attack, stroke, heart failure)
- Kidney diseases (such as chronic kidney disease, kidney transplant, renal insufficiency such as renal failure requiring dialysis)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Henry Ford Health System
Detroit, Michigan, 48202
Menghua Tao, Ph.D., 3138768471, mtao1@hfhs.org
About this study
Official title: Impacts of Peanut Intake on Hepatic Markers and Gut Microbiota in Adults With MASLD
The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver. The main goal is to investigate if patients who consume peanuts have improved liver marker tests as well as metabolic profile. We will also investigate how peanuts alter the gut microbes and liver fat content in patients with metabolic associated fatty liver.
- Participants will be randomized into intervention (peanut consumption for 12 weeks) and control (regular diet) arm.
- Stool sample and blood (for biomarkers) collection across both arms at baseline and post-intervention
- Daily log to be completed for tracking peanut consumption
- 2-day Dietary recall at baseline, during Week 6 and Week 12
- Poat intervention Fibro scans for participants with baseline scans available
- Conditions
- MASLD, Fatty Liver
- Being tested
- Peanut consumption
- Keywords
- fatty liver, masld, peanut, hepatic, intervention, gut microbe
- Medical subject headings
- Fatty Liver
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Peanut consumptionOther
MASLD patients will consume 50 gm of peanut daily for 12 weeks
| Study group | Role | What they receive |
|---|---|---|
| Peanut | Experimental | MASLD patients will consume 50 gm of peanut daily for 12 weeks Receives: Other: Peanut consumption |
| Control | No intervention | Regular diet |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hepatic Markers
Changes in hepatic markers such as ALT, ASP, ALP will be evaluated through blood tests at baseline and post-intervention
Measured: Baseline to post-intervention (12 weeks)
Secondary outcomes (3)
Metabolic Profile
Investigate change in metabolic profiles i.e., total cholesterol, HDL-C, LDL-C, triglycerides, glucose, hemoglobin A1C (HBA1C), and insulin over 12 weeks
Measured: Baseline to post-intervention (12 weeks)
Gut microbiota composition
Investigate whether MASLD patients in the Peanut arm will have improved gut microbiota compositions than those in the Control arm
Measured: Baseline to post-intervention (12 weeks)
Intrahepatic fat content
Explore whether MASLD patients in the Peanut arm may have lower intrahepatic fat content (IHF) than those in the Control arm over 12 weeks
Measured: Baseline to post-intervention (12 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jun 2026
- Study start9 Jun 2026
- Primary completion6 Apr 2028 (estimated)
- Study completion9 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MASLDStudies of the same condition, open and under way.
- More trials run by Henry Ford Health SystemThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 125 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Henry Ford Health System
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Menghua Tao, Henry Ford Health System
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07646197
- Sponsor's protocol ID
- 19113
- Other IDs
- F20581
- Status last verified
- Jun 2026
- First submitted
- 9 Jun 2026
- Last updated
- 6 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impacts of Peanut Intake on Hepatic Markers and Gut Microbiota in Adults With MASLD
- ClinicalTrials.gov ID
- NCT07646197
- Acronym / sponsor ID
- 19113
- Conditions
- MASLD, Fatty Liver
- Keywords
- fatty liver, masld, peanut, hepatic, intervention, gut microbe
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 125 participants (estimated)
- Lead sponsor
- Henry Ford Health SystemUniversity, hospital or other
- Study start
- 9 Jun 2026 (actual)
- Primary completion
- 6 Apr 2028 (estimated)
- Study completion
- 9 Jun 2028 (estimated)
- First posted
- 12 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver. The main goal is to investigate if patients who consume peanuts have improved liver marker tests as well as metabolic profile. We will also investigate how peanuts alter the gut microbes and liver fat content in patients with metabolic associated fatty liver.
- Participants will be randomized into intervention (peanut consumption for 12 weeks) and control (regular diet) arm.
- Stool sample and blood (for biomarkers) collection across both arms at baseline and post-intervention
- Daily log to be completed for tracking peanut consumption
- 2-day Dietary recall at baseline, during Week 6 and Week 12
- Poat intervention Fibro scans for participants with baseline scans available
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Peanut | Experimental | Other: Peanut consumptionMASLD patients will consume 50 gm of peanut daily for 12 weeks |
| Control | No intervention | –Regular diet |
Who may qualify
- Ages
- 30 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- 30-70 years
- do not consume peanut/peanut butter/treenut/seeds > /week
- at least one encounter-related (stage F0/F1) MASLD diagnosis (K76.0)
- Able to understand, speak, and read English
- Mentally competent to consent
Key exclusion criteria (7 listed)
- Food allergy to peanuts or peanut-containing products
- With alcohol use disorder (AUDIT screening)
- Leukemia
- Lymphoma
- Other types of cancer
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Peanut consumptionMASLD patients will consume 50 gm of peanut daily for 12 weeks | Other | Peanut |
Primary outcome
Hepatic Markers
Time frame: Baseline to post-intervention (12 weeks)
Changes in hepatic markers such as ALT, ASP, ALP will be evaluated through blood tests at baseline and post-intervention
3 secondary outcomes
Metabolic Profile
Time frame: Baseline to post-intervention (12 weeks)
Gut microbiota composition
Time frame: Baseline to post-intervention (12 weeks)
Intrahepatic fat content
Time frame: Baseline to post-intervention (12 weeks)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2026.
Related trials for MASLD
Not yet recruitingObservational study
Periodontal Status and Biomarkers in MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Recruiting
NAFLD Clinical Care Pathway
NAFLD, MASLD
Enrolling by invitation
Effect of Ancestry Supplementation in Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
MASLD
RecruitingPhase 3
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Not yet recruiting
Personalized Dietary Feedback to Reduce Hepatic Steatosis in Patients With MASLD
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), MetALD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Peanut consumption in people with MASLD and Fatty Liver, run by Henry Ford Health System at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Menghua Tao, PhD (313-590-9408, mtao1@hfhs.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hepatic Markers (time frame: Baseline to post-intervention (12 weeks)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2026; AzTrials last refreshed its copy on 7 Nov 2026.